Boston Scientific Corp. named Michael Mahoney of Johnson & Johnson its next chief executive officer as the world’s second-largest maker of implantable heart devices seeks to expand its product line and return to profitability.
Boston Scientific Corp. won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said.
Boston Scientific Corp.’s Michael Mahoney, who took the helm yesterday as chief executive officer, says innovation and smooth integration of recent acquisitions will return the company to growth next year.
Boston Scientific Corp.’s Watchman improved survival in patients with erratic heart rates after four years, an unexpected finding that may help create a $500 million market, said Chief Executive Officer Michael Mahoney.
MetroPCS Communications Inc., the wireless carrier looking to expand, may struggle to become a viable replacement for T-Mobile USA as AT&T Inc. tries to win government approval to buy the company from Deutsche Telekom AG.